Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors

A dataset from 2026 describes 1,7-naphthyridinone derivatives designed as dual inhibitors of the kinases PKMYT1 and WEE1. It was authored by Bo Chen and shared on figshare, containing data on compound potency, selectivity, and in vitro ADME profiles. The dataset is 3.3 KB in size.

Use Cases

• Training ML models to predict kinase inhibitor potency based on structural modifications described.
• Analyzing structure-activity relationships for compounds targeting the G2/M checkpoint.
• Benchmarking new dual PKMYT1/WEE1 inhibitors against the reported compound 24.
• Studying the correlation between NanoBRET assay results and cellular pCDK1 inhibition.

Strengths

• Includes specific potency metrics, such as a pCDK1 T14 IC50 of 4.9 nM for the lead compound.
• Data is associated with peer-reviewed research concepts, including kinome selectivity profiling and organoid efficacy testing.
• File size is 3.3 KB, indicating a focused and likely well-defined dataset.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from chemical synthesis and biological assays.

Freshness

Last updated 2026-04-20 10:03:24; freshness should be verified.